A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined with Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma

Grants and Contracts Details

StatusActive
Effective start/end date6/14/223/29/23

Funding

  • Rakuten Medical Incorporated: $20,718.00